ATG-031

• Description:

  ATG-031 is a humanized anti-CD24 monoclonal antibody with high affinity and specificity. ATG-031 interacts with Siglec-10 expressed by tumor-associated macrophages. ATG-031 effectively stimulates macrophage-mediated phagocytosis and induces cancer cell destruction by blocking the anti-phagocytic surface proteins. ATG-031 can be used in the study of haematological malignancies as well as solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1][2][3].

• UNSPSC:

  12352203

• Target:

  Others

• Type:

  Inhibitory Antibodies

• Related Pathways:

  Others

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/atg-031.html

• Purity:

  99

• Solubility:

  10 mM in DMSO

• Smiles:

  [ATG-031]

• Molecular Weight:

  (146.305 kDa)

• References & Citations:

  [1]Peng Chen, et al., (2022) . ATG-031, a first-in-class anti-CD24 antibody, showed potent preclinical anti-tumor efficacy by blocking “don’t-eat-me” signal. Journal for ImmunoTherapy of Cancer 2022.|[2]Peng Chen, et al., Abstract 6641: ATG-031, a first-in-class humanized anti-CD24 antibody, demonstrates potent in vivo efficacy and repolarizes tumor-associated macrophages in the TME. Cancer Res 1 April 2023; 83 (7_Supplement) : 6641.|[3]Chen P, et al., 1337 The preclinical characterization and translational research of ATG-031, a first-in-class humanized anti-CD24 antibody, for the treatment of solid tumors and hematological malignanciesJournal for ImmunoTherapy of Cancer 2023;11

• Shipping Conditions:

  Dry Ice

• Storage Conditions:

  Store at -80°C for 2 years

• Scientific Category:

  Inhibitory Antibodies

• Clinical Information:

  Phase 1